ACTIVE
CLINICAL TRIALS (ENROLLING)
|
GSK EPZ113734:
A prospective, randomized, multicenter, open-label study to compare the efficacy and safety of simplifying from a regimen of Atazanavir + Ritonavir + Tenofovir/Emtricitabine to Atazanavir + Abacavir/Lamivudine without Ritonavir for 48 weeks in virologically supressed, HIV-1 infected, HLAB 5701 negative subjects. |
Kendle
NP303-101:
Randomized Double-Blind, Parallel-Group, Placebo-Controlled, Two-Stage
Study to asses the efficacy and safety of Crofelemer 125mg, 250mg, and
500mg Orally Twice Daily for Treatment of HIV-Associated Diarrhea
(ADVENT Trial) |
Pfizer A4001067 (POEM):
An international, multicenter, prospective observational study of the
safety of Maraviroc used with optimized background therapy in
treatment-experienced HIV-1 infected patients |
Pfizer A4001078
(Phase III):
Novel combinations of Maraviroc and other antiretroviral agents for the
treatment of treatment naïve HIV infected patients with R5 HIV-1. |
Pfizer A4001080
(Phase III):
A multicenter randomized open comparative trial of Maraviroc versus
Etravirine each in combination with Darunivir/Ratinavir and Raltegravir
for the treatment of antiretroviral-experienced- HIV-1 infected
subjects co-infected with Hepatitis B and/or Hepatitis C. |
Pfizer A5271022
(Phase II):
Multicenter, randomized, comparative trial of UK-453, 061, in
combination with Atazanavir/Ritonavir versus nucleotide/ nucleoside
reverse transcriptase inhibitors as optimized background therapy in
combination with Atazanavir/Ritonavir for the treatment of
NNRTI-experienced HIV-1 infected subjects. |
BioCollections Worldwide, Inc. (BCW) 2009-6967:
A point in time, multisite, prospective blood collection protocol in order to build a repository of specimens from Donor/Participants that are diagnosed with HIV exclusively. |
ONGOING
HIV TRIALS (NOT ENROLLING)
|
|
Boehringer Ingelheim
1100.1526 (Phase III):
An open label randomized parallel group study to assess the efficacy
and safety of switching HIV-1 infected patients successfully treated
with a Nevirapine IR 200mg BID based regimen.
|
Merck Protocol
0518-071 (Phase III):
To evaluate the antiretroviral activity of once a day Raltegravir, 800
mg q.d. Compared to twice a day Raltegravir 400 mg b.i.d., each in
combination therapy with Truvada. |
Merck Protocal V526-001 (Phase I):
A dose ranging study of the safety, tolerability, and immunogenicity of a 3-dose regimen of the MRK Ad5 HIV-1 Trigene and the MRK Ad6 HIV-1 Trigene vaccines alone and in combination in healthy adults.
|
Merck
Protocol
021-00
A multi-center, double-blind, randomized, placebo-controlled
Study to Evaluate the Safety and Antiretroviral Activity of MK
0518 Versus Efavirenz in Treatment Naive HIV Infected Patients,
Each in Combination with TRUVADA. |
Merck Protocol
0518-055 (Phase III):
To evaluate the safety and tolerability of Raltegravir 400 mg b.i.d. in
combination with other antiretroviral agents. Male/female African
American, 16 years of age and older. |
BI 1100.1486
- A double-blind, randomized, double-dummy,
parallel group active control trial to evaluate the anti-viral efficacy
of
400mg QD Nevirapine extended release formulation in comparison to 200mg
BID
Nevirapine immediate release in combination with Truvada in
anti-retroviral
therapy naive HIV1 infected patients.
|
.jpg)
.jpg)
.jpg)
.jpg)
